<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="marinedrugs-17-00567-t003" orientation="portrait" position="float">
 <object-id pub-id-type="pii">marinedrugs-17-00567-t003_Table 3</object-id>
 <label>Table 3</label>
 <caption>
  <p>Drug combination results with GRFT.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Line</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Assay Readout</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Combination Drug</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Result</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBMCs and CD4+ MT-4 cells</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p24 HIV-1 core Ag ELISA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tenofovir, maraviroc, and enfuvirtide</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B29-marinedrugs-17-00567" ref-type="bibr">29</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HeLa-ADA effector cells and HeLa-P5L CCR5-bearing target cells</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCR5-tropic cell-cell fusion</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Covalently linked gp41-binding peptide C37</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B32-marinedrugs-17-00567" ref-type="bibr">32</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TZM-bl cells, U87-CCR5 and U87-CXCR4.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pseudovirus neutralization</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2G12 mAb</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B26-marinedrugs-17-00567" ref-type="bibr">26</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Persistently HIV-infected T cells and noninfected CD4+ target T cells</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Giant cell formation</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Efavirenz, tenofovir, raltegravir, and elvitegravir</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Raji.DC-SIGN cells</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DC-SIGN mediated HIV transmission</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tenofovir, saquinavir, and 2G12 mAb</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MT-4 cells, PBMC</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus-induced cytopathic effect</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microvirin, 2G12 mAb, BanLec, and HHA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synergy</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B28-marinedrugs-17-00567" ref-type="bibr">28</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
